Abstract
![]() |
Interplay between AIT and biologics in modulating allergic inflammation. |
Key Messages
- The combination of allergen immunotherapy (AIT) with biologics represents a promising approach in the field of allergy treatment.
- Omalizumab (anti-IgE) enhances the safety and tolerability of AIT while providing additional evidence of efficacy compared with AIT alone.
- Combining dupilumab (anti–interleukin-4 receptor) with AIT for 16 weeks reduces adverse effects and improves the immunologic profile but does not significantly enhance short-term efficacy.
- Cat dander subcutaneous immunotherapy with tezepelumab (anti-thymic stromal lymphopoietin) for 1 year enhances AIT efficacy, with durable suppression of symptom scores and immune response at 1 year after discontinuation compared with subcutaneous immunotherapy alone.
- Further investigation is required to assess the long-term benefits, safety, and optimal dosing schedules of AIT and biologics combination strategy.
No comments:
Post a Comment